What is Citius Oncology, Inc.'s commercial sales milestones?

Citius Oncology, Inc. (CTOR) reported commercial sales milestones of $300M in Q4 2025.

What does commercial sales milestones mean?

Captures potential future payments due to partners or licensors upon reaching specific revenue or market penetration targets for a commercialized product. This metric highlights the long-term financial obligations tied to the successful market adoption of the company's products. It serves as a proxy for the expected commercial success and associated royalty or milestone burdens.

Citius Oncology, Inc. CTOR Commercial Sales Milestones

Commercial Sales Milestones at other companies

Tarsus Pharmaceuticals, Inc.TARS

$92M—

Tarsus Pharmaceuticals, Inc.TARS

$77M0.0%

Tarsus Pharmaceuticals, Inc.TARS

$102M0.0%

Climb Bio, Inc.CLYM

$8M—

ZymeworksZYME

$216.75M—

Halozyme TherapeuticsHALO

$0-100%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:CommercialSalesMilestones.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s commercial sales milestones.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s commercial sales milestones?: Citius Oncology, Inc. (CTOR) reported commercial sales milestones of $300M in Q4 2025.
What does commercial sales milestones mean?: Captures potential future payments due to partners or licensors upon reaching specific revenue or market penetration targets for a commercialized product. This metric highlights the long-term financial obligations tied to the successful market adoption of the company's products. It serves as a proxy for the expected commercial success and associated royalty or milestone burdens.